FBIO

+ Watchlist + Portfolio

Fortress Biotech, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.85
52-Week Range: $2.18 – $4.53
Market Cap: $92.38M
P/E (TTM): 1.03
EPS (TTM): 2.70
Dividend Yield: —

Advanced Metrics

Price/Book: 0.56
PEG Ratio: —
Return on Equity: 115.98%
Return on Assets: -7.65%
Gross Margin: 63.86%
Operating Margin: -53.46%
Profit Margin: 163.32%
Current Ratio: 3.96
Debt/Equity: 0.26
Total Debt: $53.32M
Free Cash Flow: $-16.89M
Revenue Growth: 14.00%
Earnings Growth: —
Enterprise Value: $-8.93M

FBIO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$75.74M	$84.51M	$57.67M	$63.26M
Cost of Revenue	$30.77M	$22.89M	$20.88M	$20.92M
Gross Profit	$44.97M	$61.62M	$36.80M	$42.34M
Research & Development	$134.88M	$106.07M	$56.88M	$11.90M
Selling, General & Admin	$113.66M	$90.98M	$87.73M	$96.40M
Operating Expenses	$248.53M	$200.82M	$148.04M	$112.56M
Operating Income	-$203.56M	-$139.20M	-$111.24M	-$70.22M
EBITDA	-$193.69M	-$135.72M	-$104.49M	-$20.16M
Pretax Income	-$213.46M	-$153.63M	-$120.54M	-$33.53M
Income Tax	$449.00K	$521.00K	$312.00K	-$620.00K
Net Income	-$86.58M	-$60.64M	-$46.00M	$6.82M
Diluted EPS	-14.55	-8.47	-2.69	-0.07
Diluted Shares	5.92M	8.11M	20.78M	27.90M

FBIO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$178.27M	$80.93M	$57.26M	$79.38M
Receivables	$28.35M	$15.39M	$10.40M	$29.94M
Inventory	$14.16M	$10.21M	$14.43M	$9.62M
Current Assets	$230.43M	$117.02M	$90.37M	$123.84M
Total Assets	$294.30M	$167.53M	$144.22M	$185.55M
Current Liabilities	$127.72M	$84.91M	$71.40M	$49.74M
Long-Term Debt	$93.14M	$60.86M	$57.96M	$59.50M
Total Debt	$127.34M	$84.66M	$75.96M	$74.30M
Total Liabilities	$244.28M	$165.94M	$145.87M	$123.36M
Retained Earnings	-$634.23M	-$694.87M	-$740.87M	-$734.05M
Shareholders' Equity	$41.72M	$22.54M	$22.74M	$49.87M
Working Capital	$102.72M	$32.11M	$18.97M	$74.10M
Net Debt	—	—	$1.32M	—

FBIO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$179.40M	-$128.22M	-$80.19M	-$65.78M
Capital Expenditure	-$3.06M	-$8.10M	-$15.00M	—
Free Cash Flow	-$182.46M	-$136.32M	-$95.19M	-$65.78M
Depreciation & Amortisation	$9.35M	$6.00M	$4.46M	$4.66M
Stock-Based Compensation	$22.99M	$17.03M	$32.62M	$28.74M
Investing Cash Flow	-$22.93M	-$2.10M	-$15.00M	$10.12M
Financing Cash Flow	$75.32M	$32.74M	$70.64M	$77.44M
Dividends Paid	-$8.78M	-$8.77M	-$4.71M	-$664.00K
Share Repurchases	-$1.20M	-$400.00K	$0.00	-$265.00K
Net Change in Cash	-$127.01M	-$97.59M	-$24.55M	$21.79M

FBIO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$13.14M	$16.41M	$17.63M	$16.08M	$16.04M
Cost of Revenue	$4.79M	$4.94M	$5.75M	$5.44M	$6.22M
Gross Profit	$8.35M	$11.47M	$11.88M	$10.64M	$9.82M
Research & Development	$3.94M	$8.13M	$208.00K	-$367.00K	$540.00K
Selling, General & Admin	$25.66M	$38.76M	$17.41M	$14.73M	$15.89M
Operating Expenses	$30.67M	$47.95M	$18.69M	$15.43M	$17.56M
Operating Income	-$22.32M	-$36.47M	-$6.81M	-$4.79M	-$7.74M
EBITDA	-$20.99M	-$8.42M	$12.43M	-$3.35M	$145.28M
Pretax Income	-$24.69M	-$11.65M	$8.85M	-$6.21M	$142.29M
Income Tax	$0.00	—	$26.00K	-$816.00K	$5.13M
Net Income	-$10.58M	$15.49M	$5.85M	-$3.94M	$110.37M
Diluted EPS	-0.48	0.45	0.11	—	2.82
Diluted Shares	26.45M	29.82M	33.10M	—	38.41M

FBIO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$91.34M	$74.39M	$86.22M	$79.38M	$255.84M
Receivables	$18.33M	$16.20M	$18.13M	$29.94M	$25.51M
Inventory	$12.50M	$12.85M	$11.82M	$9.62M	$9.29M
Current Assets	$126.90M	$110.40M	$118.50M	$123.84M	$295.48M
Total Assets	$178.07M	$159.90M	$181.41M	$185.55M	$356.87M
Current Liabilities	$73.67M	$57.52M	$54.07M	$49.74M	$103.39M
Long-Term Debt	$56.38M	$50.03M	$47.77M	$59.50M	$36.88M
Total Debt	$74.24M	$69.22M	$68.29M	$74.30M	$53.63M
Total Liabilities	$145.59M	$122.51M	$116.22M	$123.36M	$154.50M
Retained Earnings	-$751.45M	-$735.97M	-$730.12M	-$734.05M	-$623.68M
Shareholders' Equity	$22.25M	$43.92M	$55.86M	$49.87M	$162.21M
Working Capital	$53.23M	$52.88M	$64.44M	$74.10M	$192.09M

FBIO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$19.56M	-$27.56M	-$6.11M	-$12.54M	$203.85M
Free Cash Flow	-$19.56M	-$27.56M	-$6.11M	-$12.54M	$203.85M
Depreciation & Amortisation	$1.19M	$1.16M	$1.16M	$1.16M	$1.22M
Stock-Based Compensation	$6.29M	$16.79M	$3.20M	$2.46M	$1.76M
Investing Cash Flow	$1.17M	$6.09M	$2.87M	$0.00	$0.00
Financing Cash Flow	$52.14M	$4.52M	$15.07M	$5.71M	-$27.39M
Dividends Paid	-$166.00K	-$166.00K	-$166.00K	-$166.00K	$0.00
Share Repurchases	-$150.00K	-$115.00K	$0.00	$0.00	-$14.34M
Net Change in Cash	$33.74M	-$16.95M	$11.83M	-$6.84M	$176.46M

Market Snapshot

About

Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products and product candidates. The company operates as a holding company with a portfolio of subsidiary companies focused on developing therapies for various diseases including cancer, rare diseases, and infectious diseases. Fortress Biotech provides strategic, operational, and financial support to its partner companies while maintaining focused development programs. The company's business model emphasizes building a diversified portfolio of clinical-stage and commercial-stage assets to reduce development risk.